Shanghai

Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors

Retrieved on: 
Monday, November 22, 2021

Previously, Dr. Gaynor spent 15 years in senior roles at Lilly Oncology, including as Senior Vice President, Clinical Development and Medical Affairs.

Key Points: 
  • Previously, Dr. Gaynor spent 15 years in senior roles at Lilly Oncology, including as Senior Vice President, Clinical Development and Medical Affairs.
  • Were pleased to welcome Richard to our Board, said Dr.Samantha Du, Founder, Chairperson and Chief Executive Officer ofZai Lab.
  • Its an honor to join the Zai Lab Board and to work alongside Samantha and her team in achieving the companys vision of becoming a global biopharmaceutical company, commented Dr. Gaynor.
  • Were excited by the collective expertise the Board will bring to Zai Lab as we strengthen our capabilities and execute our global strategy.

NIO Inc. Announces Completion of At-The-Market Offering of American Depositary Shares

Retrieved on: 
Friday, November 19, 2021

SHANGHAI, China, Nov. 19, 2021 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO) (NIO or the Company), a pioneer and a leading company in the premium smart electric vehicle market, today announced that it has completed its previously announced at-the-market offering (the At-The-Market Offering) of American depositary shares (ADSs), each representing one Class A ordinary share of the Company.

Key Points: 
  • SHANGHAI, China, Nov. 19, 2021 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO) (NIO or the Company), a pioneer and a leading company in the premium smart electric vehicle market, today announced that it has completed its previously announced at-the-market offering (the At-The-Market Offering) of American depositary shares (ADSs), each representing one Class A ordinary share of the Company.
  • The Company currently plans to use the net proceeds from the At-The-Market Offering to further strengthen its balance sheet, as well as for general corporate purposes.
  • NIO Inc. is a pioneer and a leading company in the premium smart electric vehicle market.
  • NIO aims to build a community starting with smart electric vehicles to share joy and grow together with users.

Bilibili Inc. Prices Offering of Convertible Senior Notes

Retrieved on: 
Friday, November 19, 2021

SHANGHAI, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Bilibili Inc. (Bilibili or the Company) (NASDAQ: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced the pricing of US$1,400 million in aggregate principal amount of convertible senior notes due 2026 (theNotes) (the Notes Offering).

Key Points: 
  • SHANGHAI, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Bilibili Inc. (Bilibili or the Company) (NASDAQ: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced the pricing of US$1,400 million in aggregate principal amount of convertible senior notes due 2026 (theNotes) (the Notes Offering).
  • In addition, the Company has granted the initial purchasers in the Notes Offering a 30-day option to purchase up to an additional US$200 million principal amount of the Notes.
  • When issued, the Notes will be senior, unsecured obligations of Bilibili.
  • This press release contains information about the pending offering of the Notes, and there can be no assurance that the Notes Offering will becompleted.

Bilibili Inc. Announces Proposed Offering of US$1,400 Million Convertible Senior Notes

Retrieved on: 
Thursday, November 18, 2021

SHANGHAI, China, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Bilibili Inc. (Bilibili or the Company) (NASDAQ: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced a proposed offering (the Notes Offering) of US$1,400 million in aggregate principal amount of convertible senior notes due 2026 (theNotes) subject to market conditions and other factors.

Key Points: 
  • SHANGHAI, China, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Bilibili Inc. (Bilibili or the Company) (NASDAQ: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced a proposed offering (the Notes Offering) of US$1,400 million in aggregate principal amount of convertible senior notes due 2026 (theNotes) subject to market conditions and other factors.
  • The Company intends to grant the initial purchasers in the Notes Offering a 30-day option to purchase up to an additional US$200 million principal amount of the Notes.
  • Concurrently with this Notes Offering, the Company may enter into separate and individually negotiated transactions with certain holders of the Companys 1.375% Convertible Senior Notes due 2026 (the 2026 Notes) to exchange their notes for the ADSs.
  • This press release contains information about the pending offering of the Notes and exchange of the 2026 Notes, and there can be no assurance that any of the Notes Offering and exchange of the 2026 Notes will becompleted.

Jiayin Group Inc. to Release Third Quarter 2021 Unaudited Results on Wednesday, November 24, 2021

Retrieved on: 
Thursday, November 18, 2021

SHANGHAI, China, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Jiayin Group Inc. (Jiayin or the Company) (NASDAQ: JFIN), a leading fintech platform in China, today announced that it will release its financial results for the third quarter 2021 before the U.S market opens on Wednesday, November 24, 2021.

Key Points: 
  • SHANGHAI, China, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Jiayin Group Inc. (Jiayin or the Company) (NASDAQ: JFIN), a leading fintech platform in China, today announced that it will release its financial results for the third quarter 2021 before the U.S market opens on Wednesday, November 24, 2021.
  • The company will conduct a conference call on Wednesday, November 24, 2021 at 8:00 AM U.S. Eastern Time (9:00 PM Beijing/Hong Kong Time).
  • Please register in advance to join the conference using the link provided below and dial in 10 minutes before the call is scheduled to begin.
  • A replay of the conference call may be accessed by phone at the following numbers until December 2, 2021.

Gracell Biotechnologies to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

Retrieved on: 
Wednesday, November 17, 2021

SUZHOU, China and PALO ALTO, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (Gracell), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29th to December 2nd.

Key Points: 
  • SUZHOU, China and PALO ALTO, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (Gracell), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29th to December 2nd.
  • The Gracell team is scheduled to hold a fireside chat that will be available on demand starting on November 22nd and will host virtual investor meetings at the conference on December 1st and 2nd.
  • A webcast of the fireside chat will be available on the "Events and Presentations" page of the Investors section of the Company's website.
  • Gracell Biotechnologies Inc.("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies.

Dada to Announce Third Quarter 2021 Unaudited Financial Results on November 23, 2021

Retrieved on: 
Wednesday, November 17, 2021

The Dada Now platform enables improved delivery experience for participants on the JDDJ platform through its readily accessible fulfillment solutions and strong on-demand delivery infrastructure.

Key Points: 
  • The Dada Now platform enables improved delivery experience for participants on the JDDJ platform through its readily accessible fulfillment solutions and strong on-demand delivery infrastructure.
  • Meanwhile, the vast volume of on-demand delivery orders from the JDDJ platform increases order volume and density for the Dada Now platform.
  • This press release contains statements that may constitute forward-looking statements pursuant to the safe harbor provisions of the U.S.
  • Statements that are not historical facts, including statements about Dadas beliefs, plans and expectations, are forward-looking statements.

Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in CIDP

Retrieved on: 
Tuesday, November 16, 2021

The ADHERE trial is a registrational, prospective, multi-center study to investigate the safety and efficacy ofweekly subcutaneous (SC) efgartigimod in adult patients with CIDP.

Key Points: 
  • The ADHERE trial is a registrational, prospective, multi-center study to investigate the safety and efficacy ofweekly subcutaneous (SC) efgartigimod in adult patients with CIDP.
  • Diagnosis of CIDP will be confirmed by an independent panel of experts prior to enrollment into Stage A.
  • In Stage B, patients are randomized to either SC efgartigimod or placebo for up to 48 weeks.
  • The primary endpoint is event-driven and based on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) overall disability score.